Status:
COMPLETED
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
Lead Sponsor:
New York State Psychiatric Institute
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cannabis Use
Eligibility:
All Genders
21-50 years
Phase:
PHASE1
PHASE2
Brief Summary
In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.
Detailed Description
In order to improve treatment outcome for cannabis use disorder (CUD), the investigators have developed a laboratory model to investigate the effects of potential treatment medications on cannabis wit...
Eligibility Criteria
Inclusion
- Current cannabis use
- Able to give informed consent and perform study procedures
- Women practicing an effective form of birth control
- English speaking
Exclusion
- Presence of any clinically significant medical diagnoses
- History of heart disease and cardiac risk factors, severe chronic obstructive pulmonary disease, uncontrolled hypertension, or diabetes
- Current parole or probation
- Certain psychiatric diagnoses
- Current pregnancy or lactation
Key Trial Info
Start Date :
September 5 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03253926
Start Date
September 5 2017
End Date
December 31 2021
Last Update
July 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032